Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy

Fig. 2

In vitro evaluation of CD22 CAR T cells. a A representative diagram of flow cytometry analysis of residual Daudi, Namalwa, Nalm-6 and K562 cells when cocultured with CAR-T cells at 0 h (upper panel) and 48 h (lower panel). b Percentage of residual Namalwa or K562 cells detected by flow cytometry after co-culturing with CAR T or VEC-T cells for 24 h at indicated E:T ratio (1:8, 1:4,1:1,4:1,8:1). c. Percentage of degranulated CAR-T cells (CD107a positive T cells/CAR positive T cells) after cocultured with Daudi, Namalwa, Nalm-6 and K562 for 24 h. d ELISA detection of IFN-γ and TNF-α in the supernatants of VEC-T or CAR-T cocultured with Daudi, Namalwa and K562 for 24 h. e Primary ALL cells were collected from 5 patients, and cocultured with CD22 CAR-T cells or vector-T cells at E:T ratio of 1:1 respectively for 48 h. The residual tumor ALL cells was defined as 7AAD−CD3−GFP−CD19+CD10+ by flow cytometry. f Percentage of degranulated CAR-T cells (CD107a positive T cells/CAR positive T cells) after cocultured with patient samples for 5 h

Back to article page